Daiichi Sankyo, the Japanese parent of Ranbaxy Laboratories, today said it believes that certain shareholders of the Indian company concealed and misrepresented critical information. The company is now pursuing legal remedies.“Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the US DOJ (Department of Justice) and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time,” Daiichi Sankyo said in a statement posted on its website.Early last week, Ranbaxy pleaded guilty of making fraudulent statements to the US food and drugs Administration (US FDA) about how it tested drugs at two of its Indian plants and agreed to pay $500 million as penalty.